key: cord-1055873-ec7nr5lk authors: Bardaji, M. J. Lostes; Aliende, E.; Moreno, M.; Oberoi, H. K.; Braña, I.; Saavedra, O.; Villar, M. Vieito; Alonso, G.; Galvao, V.; Carballo, N.; Beltran, M.; Rovira, P.; Cidoncha, I.; Manich, C. Saura; Mercade, T. Macarulla; Oaknin, A.; Galceran, J. Carles; Felip, E.; Garralda, E.; Pujol, S. Perez title: 1623P Phase I clinical trials (CT) forge on despite COVID-19 date: 2021-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2021.08.1616 sha: 4d9d5274cacd53dee3d9bfa90c70092ece3f19fc doc_id: 1055873 cord_uid: ec7nr5lk nan Results: All sites report relatively low rates of confirmed SARS-COV-2 infection (range, 0-83 cases) with a wide range in the case fatality rate (0-50%). With a median duration of 2.3 months (IQR .9-4.2 months), all sites report a temporary lock down with no (12.5%), minimal (12.5%), moderate (50%) and severe (25%) impact on patient care. Examples of this impact include intra-city travel restrictions (25%), intercity travel restrictions (62.5%), and excessive patient travel costs (75%). Most sites report changes in radiation therapy (RT) delivery strategies including transition to hypofractionation (50%), selection of single fraction RT for metastasis palliation (62.5%), deferral of RT for low-risk adjuvant situations (37.5%), or no change (25%). Changes in chemotherapy delivery strategies include transition to oral options (37.5%), use of hormone therapy over chemotherapy (37.5%), deferral of palliative chemotherapy (50%), and delivery of RT without concurrent chemotherapy (12.5%), or no change (50%). A total 3 sites (37.5%) reported the existence of breast or cervical cancer screening programs prior to the pandemic. Only one site reported return to pre-pandemic levels of cancer screening. HPV vaccination programs were active at 2 sites prior to the pandemic with only partial recovery at one site. Conclusions: The pandemic has challenged cancer patients despite relatively low rates of reported infection and death. To minimize transmission, oncologist utilize treatment strategies minimizing patient time in hospital. The negative impact on the limited screening and preventative services in SSA is concerning for an impact that may continue for years to come. Legal entity responsible for the study: The authors. Conclusions: Despite COVID19 and an initial decrease of new studies during 2020, the number of new proposals for phase I CT is increasing in 2021. This appears to be equal for biotech and big pharma proposals. Remote PSSVs are an efficient alternative to on-site visits. Digitalization and measures taken are effective to maintain the Clinical trial start up activity in VHIO and will probably remain after the pandemic is over. Background: The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly in making timely cancer diagnosis. Our public health system has been concerned about potential delays leading to a higher proportion of patients with advanced stages. Our cancer diagnosis fast-track program (CFP) in the Clinic-Malvarrosa Health department in Valencia (Spain) is connecting primary care (PC) with different specialists to speed cancer diagnosis and treatment upon well founded suspicion. A 10-year evaluation of our CFP has recently been published. The aim of this analysis was to investigate the impact of the COVID-19 pandemic on the CFP. We analysed the programme flow during the state of emergency starting on March 16, 2020 for one year. During that year, 975 suspected cancer cases were submitted to the CFP. The submissions only decreased during the times of highest COVID-19 incidence and stricter lockdown (March, April and October 2020). However, referrals were slightly higher than in the two previous years (average 877). Of those 975 patients, 817 were seen by the corresponding specialist. A cancer diagnosis was confirmed in 197 (24.1%) with 33% urological, 23% breast, 16% gastrointestinal and 9% lung cancer. Median time from referral to the specialist visit was 13 (interquartile range, 8 to 22 days) days and a diagnosis was reached in a median of 18 days (interquartile range, 10 to 30 days). In cancer patients, treatment was started in around 30 days (interquartile range, 13.5 to 51 days) from the time of diagnosis. Sixty-one percent of cancers were found in an early stage, 20% in a locally advanced stage, and 19% in an advanced stage. These intervals and proportions were similar to the previous years. Conclusions: Our programme has proven to be a reliable tool to help PC physicians referring patients with cancer suspicion cancer, maintaining its normal flow and efficacy despite the current pandemic. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Background: Technology in healthcare has been evolving with an amplified use over the last year, due to the coronavirus 19 (COVID-19) pandemic. Face-to-face consultations for cancer patients were reduced and virtual clinics (VCs) in the form of telephone or video were offered in replacement. The aim of the study was to assess the experiences of VCs in cancer care amongst patients and healthcare professionals at Barts Health NHS Trust. Methods: Patients were identified from the electronic patient system who had received cancer care at Barts Health NHS Trust from 01/09/20-15/01/21 and attended at least one VC. Clinicians actively working within cancer were invited if they had attended at least one VC. Individual semi-structured telephone interviews were Research Grant: Bayer; Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Grant: Hallozyme; Financial Interests, Institutional Advisory Board: Clovis Oncology; Financial Interests, Personal, Advisory Board: Deciphera Pharmaceuticals; Financial Interests, Personal, Advisory Board: Genmab; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Immunogen; Financial Interests, Personal, Advisory Board: Mersana Therapeutics; Financial Interests, Personal, Advisory Board: PharmaMar; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Tesaro; Financial Interests, Personal, Other, Travel and accommodation: AstraZeneca; Financial Interests, Personal, Other, Travel and accommodation: PharmaMar; Financial Interests, Personal, Other, Travel and accommodation: Roche; Financial Interests, Personal, Advisory Board: Merck Sharps & Dohme de España, SA; Financial Interests, Institutional, Funding: Abbvie Deutschland; Financial Interests, Institutional, Funding: Advaxis Inc.; Financial Interests, Institutional, Funding: Aeterna Zentaris; Financial Interests, Institutional, Funding: Amgen; Financial Interests, Institutional, Funding: Aprea Therapeutics AB; Financial Interests, Institutional, Funding: Clovis Oncology Inc; Financial Interests, Institutional, Funding: EISAI limited LTD; Financial Interests, Institutional, Funding: F. Hoffmann eLa Roche LTD; Financial Interests, Institutional, Funding: Regeneron Pharmaceuticals; Financial Interests, Institutional, Funding: Immunogen Inc; Financial Interests, Institutional, Funding: Merck, Sharp & Dohme de España SA; Financial Interests, Institutional, Funding: Millennium Pharmaceuticals Inc; Financial Interests, Institutional, Funding: Phar-maMar SA; Financial Interests, Institutional, Funding: Tesaro Inc.; Financial Interests, Institutional, Funding: Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Executive Board member as a Co-Chair: GEICO; Non-Financial Interests, Leadership Role, Phase II Committee and Cervix Cancer Committee Representative on behalf of GEICO: GCIG; Non-Financial Interests, Officer, Faculty Member Gyneacological Track for ESMO 2018 and Chair of Gyneacological Track for ESMO 20: ESMO; Non-Financial Interests Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board: Johnson & Johnson; Financial Interests, Personal, Advisory Board: MSD Oncology Advisory Board: Sanofi; Financial Interests, Institutional, Invited Speaker: Janssen-Cilag International NV; Financial Interests, Institutional, Invited Speaker: Laboratoires Leurquin Mediolanum SAS; Financial Interests, Institutional, Invited Speaker: Lilly, S.A; Financial Interests, Institutional, Invited Speaker: Medimmune; Financial Interests, Institutional, Invited Speaker: Novartis Farmacéutica, S.A; Financial Interests, Institutional Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: Glaxo Smith Kline; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Medical Trends; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Puma; Financial Interests Bristrol Meyers Squibb; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: Medscape; Financial Interests, Personal, Invited Speaker: Merck Sharp & Dome; Financial Interests, Personal, Invited Speaker: Peervoice; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Springer; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Medical Trends; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Merck Serono; Financial Interests, Personal, Advisory Board: Peptomyc; Financial Interests, Personal, Advisory Board: Regeneron; Financial Interests, Personal, Advisory Board: Syneos Health; Financial Interests, Personal, Advisory Board: F. Hoffmann-La Roche; Financial Interests, Personal, Invited Speaker, Independent member: Grifols; Financial Interests, Institutional, Invited Speaker, Clinical Trial: F. Hoffmann-La Roche Ltd; Financial Interests, Institutional, Invited Speaker Clinical Trial: Janssen Cilag International NV; Financial Interests, Institutional, Invited Speaker, Clinical Trial: GlaxoSmithKline Research & Development Limited; Financial Interests, Institutional, Invited Speaker, Clinical Trial: Abbvie Deutschland GmbH & Co KG; Financial Interests, Institutional, Invited Speaker, Clinical Trial: Novartis Farmaceutica SA; Financial Interests, Institutional, Invited Speaker, Clinical Trial: Bayer Consumer Care AG; Financial Interests, Institutional, Invited Speaker, Clinical Trial: Takeda Pharmaceuticals International; Financial Interests, Institutional, Invited Speaker Clinical Trial: Mirati Therapeutics Inc; Non-Financial Interests Member of ESMO Nominating Committee and Compliance Committee: ESMO; Non-Financial Interests Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: F.Hoffmann/La Roche; Financial Interests, Personal, Invited Speaker: Ellipses Pharma; Financial Interests, Personal, Advisory Board: Neomed Therapeutics1 Inc; Financial Interests, Personal Janssen Global Services; Financial Interests, Personal, Invited Speaker: Seattle Genetics; Financial Interests, Personal, Expert Testimony: TFS; Financial Interests, Personal, Advisory Board: Alkermes; Financial Interests, Personal, Advisory Board: Thermo Fisher; Financial Interests, Personal, Invited Speaker: Bristol-Mayers Squibb; Financial Interests, Personal, Advisory Board: MabDiscovery; Financial Interests, Personal Funding: Novartis; Financial Interests, Institutional, Funding: Roche; Financial Interests, Institutional, Funding: Thermo Fisher; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Funding: Taiho; Other, Other, Institutional Travel Grant: Bristol-Mayers Squibb; Other, Other, Institutional Travel Grant: MSD; Other, Other, Institutional Travel Grant: Menarini; Other, Other, Institutional Travel Grant: Glycotope 1624P Impact of the COVID-19 pandemic in the cancer fast-track programme Department of Radiodiagnosis Legal entity responsible for the study: The authors.